Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 1.00 |
| ▸ | TTR | P02766 | 1/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 13/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MGAM | O43451 | 1/20 | 0.64 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.64 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.64 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
| ▸ | DHODH | Q02127 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanthohumol SCHEMBL30169731 | 1.00 | PDPK1 (1.00) | PDPK1TTRALOX5ABCB1MAPT | |
| Xanthohumol SCHEMBL143683 | 1.00 | PDPK1 (1.00) | PDPK1TTRALOX5ABCB1MAPT | |
| SCHEMBL26539037 | 0.97 | PDPK1 (0.93) | PDPK1TTRALOX5ABCB1MAPT | |
| SCHEMBL30630210 | 0.97 | PDPK1 (0.93) | PDPK1TTRALOX5ABCB1MAPT | |
| SCHEMBL16450254 | 0.92 | PDPK1 (0.86) | PDPK1TTRALOX5ABCB1MAPT | |
| SCHEMBL144848 | 0.92 | ABCB1 (0.85) | PDPK1TTRALOX5ABCB1MAPT | |
| SCHEMBL16174029 | 0.91 | ABCB1 (0.86) | PDPK1TTRALOX5ABCB1MAPT | |
| SCHEMBL26538024 | 0.91 | PDPK1 (0.84) | PDPK1TTRALOX5ABCB1MAPT | |
| SCHEMBL31415696 | 0.91 | PDPK1 (0.84) | PDPK1TTRALOX5ABCB1MAPT | |
| Xanthogalenol SCHEMBL30259154 | 0.91 | PDPK1 (0.84) | PDPK1TTRALOX5ABCB1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2249641-B1 | NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES | FLAXAN GMBH & CO KG (DE) | 2016-01-06 | — | — | EP | claimed |
| US-9006293-B2 | Compositions containing xanthohumol-cyclodextrin complexes | FLAXAN GMBH & CO. KG (DE) | 2015-04-14 | — | — | US | claimed |
| US-20110207697-A1 | XANTHOHUMOL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES OR DISORDERS | BETAL, LLC (US) | 2011-08-25 | — | — | US | claimed |
| JP-2011513308-A | — | — | 2011-04-28 | — | — | JP | claimed |
| US-20110086815-A1 | NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES | FLAXAN GMBH & CO. KG (DE) | 2011-04-14 | — | — | US | claimed |
| EP-2274411-A1 | XANTHOHUMOL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES OR DISORDERS | BETAL LLC (US) | 2011-01-19 | — | — | EP | claimed |
| EP-2249641-A1 | NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES | Flaxan GmbH & Co. KG (US) | 2010-11-17 | — | — | EP | claimed |
| WO-2009126320-A1 | XANTHOHUMOL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES OR DISORDERS | BETAL, LLC (US) | 2009-10-15 | — | — | WO | claimed |
| WO-2009108379-A1 | NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES | FLAXAN GMBH & CO. KG (US) | 2009-09-03 | — | — | WO | claimed |
| US-12636261-B2 | Treatment of inflammation initiated by the spinal cord injury, the traumatic brain injury, stroke, in inhibition of cerebral and spinal cord edema and of inflammation in neurodegenerative, immune mediated and infectious diseases of the central nervous system | Kwiecien, Jacek M. (CA) | 2026-05-26 | — | — | US | disclosed |
| US-20250221944-A1 | COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT | KBLUEBIO INC (KR) | 2025-07-10 | — | — | US | disclosed |
| EP-4506328-A1 | COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT | KBlueBio Inc (KR) | 2025-02-12 | — | — | EP | disclosed |
| US-20220395474-A1 | Treatment of inflammation initiated by the spinal cord injury, the traumatic brain injury, stroke, in inhibition of cerebral and spinal cord edema and of inflammation in neurodegenerative, immune mediated and infectious diseases of the central nervous system. | KWIECIEN JACEK M (CA) | 2022-12-15 | — | — | US | disclosed |
| US-9956199-B2 | Chromane-like cyclic prenylflavonoids for the medical intervention in neurological disorders | Aigner, Ludwig (DE) | 2018-05-01 | — | — | US | disclosed |
| EP-1937819-A4 | DNA SEQUENCES INVOLVED IN PRENYLFLAVONOID BIOSYNTHESIS IN HOPS AND THEIR USE IN MODIFYING PRENYLFLAVONOID PRODUCTION IN PLANTS | CA NAT RESEARCH COUNCIL (CA) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008095122-A2 | METHODS OF REDUCING 15-F2T-ISOP LEVELS IN MAMMALS | BIOACTIVES, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| EP-1937819-A2 | DNA SEQUENCES INVOLVED IN PRENYLFLAVONOID BIOSYNTHESIS IN HOPS AND THEIR USE IN MODIFYING PRENYLFLAVONOID PRODUCTION IN PLANTS | National Research Council of Canada (CA) | 2008-07-02 | — | — | EP | disclosed |
| US-20070092551-A1 | Therapeutic agent | TAKARA BIO INC. (JP) | 2007-04-26 | — | — | US | disclosed |
| WO-2007028239-A2 | DNA SEQUENCES INVOLVED IN PRENYLFLAVONOID BIOSYNTHESIS IN HOPS AND THEIR USE IN MODIFYING PRENYLFLAVONOID PRODUCTION IN PLANTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2007-03-15 | — | — | WO | disclosed |
| EP-1623704-A1 | THERAPEUTIC AGENT | TAKARA BIO INC. (JP) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636261-B2 | Treatment of inflammation initiated by the spinal cord injury, the traumatic brain injury, stroke, in inhibition of cerebral and spinal cord edema and of inflammation in neurodegenerative, immune mediated and infectious diseases of the central nervous system | DCX, SMN1; SMN2, CD68 | PDPK1 1570/4885TTR 1509/4885ALOX5 1179/4885 |
| US-20070092551-A1 | Therapeutic agent | FABP4, GPR119, IAPP | PDPK1 312/4885TTR 838/4885ALOX5 2519/4885 |
| US-20250221944-A1 | COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT | MCL1, CRBN, BCL3 | PDPK1 36/4885TTR 3886/4885ALOX5 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.